Previsioni

Il prezzo obiettivo medio degli analisti è +15,46€ (+96,94%). La mediana è +15,46€ (+96,94%).

Acquista	17
Mantieni	3
Vendi	3

Notizie Vai al feed delle notizie

Novavax: option volume hits multi-month high, put options dominate

Total Novavax option volume rose to 13,629 contracts by Friday. Call volume was 1,518 contracts (highest since April 18, 2024), put volume 12,111 contracts (highest since December 16, 2025). Two $8 puts dominated trading: 5,708 contracts expiring July 31, 2026 (open interest 91) and 5,675 contracts expiring July 17, 2026 (open interest 10,878). The stock fell 2.5% to $9.16. » Altro su de.investing.com
Novavax boosts partner revenues after strategy shift and beats Q1 expectations

Novavax reported revenue of USD 140 million and earnings per share of -0.06 USD in Q1 2026, both notably above expectations. The company is shifting its business model to a licensing and partnership model for the Matrix-M adjuvant technology; adjusted partner revenues rose by more than 100% year over year. Sanofi and Pfizer provided meaningful upfront payments and milestone potential, and cash and cash equivalents stood at USD 818 million. For 2026 Novavax reiterates revenue guidance of USD 230–270 million and aims for non-GAAP profitability by 2028, but continues to see execution risks from partner dependence and pipeline progress. » Altro su de.investing.com
B. Riley raises Novavax price target as governance changes and positive Phase 4 data boost outlook

B. Riley increased its Novavax price target from $16 to $18 and kept a Buy rating, citing potential shareholder-driven governance and cost-structure changes that could strengthen the balance sheet. Separately, Sanofi and Novavax reported COMPARE Phase 4 results showing Nuvaxovid had significantly lower systemic reactogenicity than Moderna's mRNA vaccine, data presented at an infectious disease conference in Munich. The trial findings support Nuvaxovid's tolerability and may aid Sanofi-led commercialization and uptake for the upcoming vaccination season. » Altro su finance.yahoo.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2012, Novavax ha già distribuito 9,39€ di dividendi. L'ultimo pagamento è avvenuto a marzo 2012.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Novavax ha registrato ricavi pari a 49,68M€ e un utile netto di −46,78M€

(EUR)	giu 2026	YoY
Ricavi	+49,68M	75,52%
Utile lordo	+37,20M	80,52%
Utile netto	−46,78M	151,77%
EBITDA	−34,93M	134,16%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+1,30Mld€
Numero di azioni	164,44M
Massimo/minimo a 52 settimane	+10,28€ - +5,33€
Dividendi	No
Beta	2,42
Rapporto P/E	−6,06
Rapporto PEG	+0,07
Rapporto P/B	−7,95
Rapporto P/S	+3,66

Profilo aziendale

Novavax, Inc. ist ein Biotechnologieunternehmen, das sich auf die Entdeckung, Entwicklung und Vermarktung von Impfstoffen zur Vorbeugung schwerer Infektionskrankheiten und zur Behandlung von Gesundheitsbedürfnissen konzentriert. Zu den Impfstoffkandidaten des Unternehmens gehören NVX-CoV2373, ein Impfstoffkandidat gegen Coronaviren, der sich in zwei Phase-III-Studien, einer Phase-IIb-Studie und einer Phase-I/II-Studie befindet; NanoFlu, ein Nanopartikel-Impfstoffkandidat gegen saisonale vierwertige Grippe, der sich in einer klinischen Phase-3-Studie befindet; und ResVax, ein Impfstoffkandidat gegen das Respiratorische Synzytialvirus (RSV) mit Fusionsprotein-Nanopartikeln. Das Unternehmen entwickelt außerdem einen RSV-F-Impfstoff, der sich in einer klinischen Phase-II-Studie für ältere Erwachsene (60 Jahre und älter) sowie in einer klinischen Phase-I-Studie für die Pädiatrie befindet. Mit Takeda Pharmaceutical Company Limited besteht eine Kooperationsvereinbarung über die Entwicklung, Herstellung und Vermarktung von NVX-CoV2373, einem COVID-19-Impfstoffkandidaten. Novavax, Inc. wurde 1987 gegründet und hat seinen Hauptsitz in Gaithersburg, Maryland.

Nome	Novavax
CEO	John Charles Jacobs
Sede centrale	Gaithersburg, md Stati Uniti
Sito web	novavax.com
Settore	Sanità
Industria	Biotecnologia
Quotazione in borsa	05/12/1995
Dipendenti	749